Education
About Us
Working with TipRanks
Follow Us
XOMA Royalty Corporation (XOMA)
NASDAQ:XOMA
XOMA Stock Chart & Stats
$25.81
$0.08(0.31%)
At close: 4:00 PM EST
$25.81
$0.08(0.31%)
Day’s Range― - ―
52-Week Range$18.35 - $39.92
Previous CloseN/A
Volume8.24K
Average Volume (3M)53.64K
Market Cap
$301.53M
Enterprise Value$361.04M
Total Cash (Recent Filing)$92.00M
Total Debt (Recent Filing)$131.91M
Price to Earnings (P/E)32.7
Beta1.36
Next Earnings
Mar 05, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.70
Shares Outstanding12,383,103
10 Day Avg. Volume49,949
30 Day Avg. Volume53,642
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)3.75
Price to Sales (P/S)10.79
P/FCF Ratio-22.33
Enterprise Value/Market Cap1.20
Enterprise Value/Revenue7.66
Enterprise Value/Gross Profit8.18
Enterprise Value/Ebitda31.95
Forecast
1Y Price Target
$71.00Price Target Upside175.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet Supports DealmakingAnalyst points to XOMA's solid cash position as a facilitator for continued creative, non-dilutive transactions and pursuit of additional licensing or partnership opportunities.
Partnership ExpansionAnalyst highlights XOMA's expanded Takeda agreement that provides royalty interests in nine additional partnered assets without a cash outlay, creating new potential royalty and milestone revenue streams.
Pipeline Monetization Via Strategic AcquisitionAnalyst notes the Generation Bio acquisition adds optionality through its collaboration with Moderna and the ctLNP delivery platform, which could lead to future outlicensing, sale proceeds, royalties, or milestone payments.
Bears Say
Clinical Trial Failure RiskAnalyst warns that Rezolute's Phase 3 miss for ersodetug removes an anticipated near-term revenue driver and increases uncertainty around milestone and royalty timing for that program.
Partner Funding And Execution RiskAnalyst observes that Generation Bio's cash burn issues leading to acquisition highlight partner execution and funding risks that could limit or delay expected royalty monetization.
Revenue Visibility And P&L ImpactAnalyst cautions that removal of a near-term revenue stream from the profit and loss statement may pressure the stock as milestone receipts become less certain and short-term revenue visibility weakens.
XOMA Royalty Corporation News
XOMA FAQ
What was XOMA Royalty Corporation’s price range in the past 12 months?
XOMA Royalty Corporation lowest stock price was $18.35 and its highest was $39.92 in the past 12 months.
What is XOMA Royalty Corporation’s market cap?
XOMA Royalty Corporation’s market cap is $301.53M.
When is XOMA Royalty Corporation’s upcoming earnings report date?
XOMA Royalty Corporation’s upcoming earnings report date is Mar 05, 2026 which is in 10 days.
How were XOMA Royalty Corporation’s earnings last quarter?
XOMA Royalty Corporation released its earnings results on Nov 12, 2025. The company reported $0.7 earnings per share for the quarter, beating the consensus estimate of -$0.04 by $0.74.
Is XOMA Royalty Corporation overvalued?
According to Wall Street analysts XOMA Royalty Corporation’s price is currently Undervalued.
Does XOMA Royalty Corporation pay dividends?
XOMA Royalty Corporation does not currently pay dividends.
What is XOMA Royalty Corporation’s EPS estimate?
XOMA Royalty Corporation’s EPS estimate is -0.11.
How many shares outstanding does XOMA Royalty Corporation have?
XOMA Royalty Corporation has 12,383,103 shares outstanding.
What happened to XOMA Royalty Corporation’s price movement after its last earnings report?
XOMA Royalty Corporation reported an EPS of $0.7 in its last earnings report, beating expectations of -$0.04. Following the earnings report the stock price went down -2.522%.
Which hedge fund is a major shareholder of XOMA Royalty Corporation?
Currently, no hedge funds are holding shares in XOMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
XOMA Royalty Corporation Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$71.00 (175.09% Upside)
$71.00 (175.09% Upside)
Insider Transactions
Bought Shares
Worth $2.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 11.1%
Last 30 Days ▼ 11.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
20.28%
12-Months-Change
Fundamentals
Return on Equity
16.22%
Trailing 12-Months
Asset Growth
-8.15%
Trailing 12-Months
Company Description
XOMA Royalty Corporation
XOMA Royalty Corp. operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
XOMA Stock 12 Month Forecast
Average Price Target
$71.00
▲(175.09% Upside)
Technical Analysis
Ocugen
―
Corvus Pharmaceuticals
―
RAPT Therapeutics
―
Monte Rosa Therapeutics
―
Inhibrx Biosciences Inc
―
Ownership Overview
13.18% Insiders
17.85% Mutual Funds
28.72% Other Institutional Investors
32.05% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---